|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0042769,
umls-concept:C0086860,
umls-concept:C0220847,
umls-concept:C0333516,
umls-concept:C0556895,
umls-concept:C0681842,
umls-concept:C0733755,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2003941,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-2
|
|
pubmed:abstractText |
The G-->A transition in the tumor necrosis factor (TNF)- alpha promoter region at position -308 (TNF308.2) and -238 (TNF238.2) were determined in 141 patients with chronic hepatitis C virus (HCV) infection. Patients received combination therapy with high-dose interferon (IFN)- alpha and ribavirin for 24 weeks. A total of 100 patients (70.9%) had a sustained virologic response (SVR) after treatment. The TNF308.2 allele was independently associated with an SVR, particularly in patients with HCV genotype 1b infection and >200,000 IU of HCV RNA/mL in serum. In conclusion, the response to combination therapy with high-dose IFN- alpha and ribavirin may be associated, at least in part, with host genetic factors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:ChangWen-YuWY,
pubmed-author:ChenShinn-CherngSC,
pubmed-author:ChuangWan-LongWL,
pubmed-author:DaiChia-YenCY,
pubmed-author:HouNai-JenNJ,
pubmed-author:HsiehMing-YenMY,
pubmed-author:HsiehMing-YuhMY,
pubmed-author:HuangJee-FuJF,
pubmed-author:LeeLi-PoLP,
pubmed-author:LinZu-YauZY,
pubmed-author:WangLiang-YenLY,
pubmed-author:YuMing-LungML
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
193
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
98-101
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16323137-Adolescent,
pubmed-meshheading:16323137-Adult,
pubmed-meshheading:16323137-Aged,
pubmed-meshheading:16323137-Antiviral Agents,
pubmed-meshheading:16323137-Drug Therapy, Combination,
pubmed-meshheading:16323137-Female,
pubmed-meshheading:16323137-Hepacivirus,
pubmed-meshheading:16323137-Hepatitis C, Chronic,
pubmed-meshheading:16323137-Humans,
pubmed-meshheading:16323137-Interferon-alpha,
pubmed-meshheading:16323137-Male,
pubmed-meshheading:16323137-Middle Aged,
pubmed-meshheading:16323137-Polymorphism, Genetic,
pubmed-meshheading:16323137-Predictive Value of Tests,
pubmed-meshheading:16323137-Promoter Regions, Genetic,
pubmed-meshheading:16323137-Ribavirin,
pubmed-meshheading:16323137-Treatment Outcome,
pubmed-meshheading:16323137-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
|
|
pubmed:affiliation |
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
